Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS
Zeitschrift für Gastroenterologie · 01.09.2024 · 62 (09) · e678
DOI: 10.1055/s-0044-1789816 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.09.2024. Verfasst von S. Loosen und 23 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Transjugular intrahepatic portosystemic shunt (TIPS) is the most effective therapy for complications of portal hypertension. However, clinical outcomes following TIPS placement vary widely between patients and identifying ideal candidates remains a challenge. Soluble urokinase plasminogen activator receptor (suPAR) is a circulating marker of immune activation that has previously been associated with liver inflammation, but its prognostic value in patients receiving TIPS is unknown.
Aim
In the present study, we evaluated the potential clinical relevance of suPAR levels in patients undergoing TIPS insertion. Methods: suPAR concentrations were measured by enzyme-linked immunosorbent assay (ELISA) in hepatic vein (HV) and portal vein (PV) blood samples from 99 patients (training cohort), as well as peripheral venous blood samples from additional 150 patients (validation cohort) undergoing TIPS placement. The association between suPAR levels and patients’ outcome was assessed using Kaplan-Meier methods and Cox-regression analyses. Results: suPAR concentrations were significantly higher in HV samples compared to PV samples and correlated with the presence of ascites, renal injury, and consequently with the Child-Pugh and MELD scores. Patients with higher suPAR levels had a significantly worse short- and long-term survival after TIPS insertion, which remained robust after adjustment for confounders in multivariate Cox-regression analyses. Sensitivity analysis showed an improvement in risk prediction in patients stratified by Child-Pugh or MELD score. In an independent validation cohort, higher levels of suPAR predicted poor transplant-free and overall survival after TIPS, particularly in patients with Child-Pugh A/B cirrhosis. Conclusion: suPAR seems to largely derive from the injured liver and its levels may predict of outcome in patients undergoing TIPS. suPAR, as a surrogate of hepatic inflammation, may be used to stratify care in patients undergoing TIPS insertion. Publication History Article published online: 26 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Loosen, S., Benz, F., Mohr, R., Reuken, P., Wirtz, T., Gu, W., Junker, L., Jansen, C., Meyer, C., Praktiknjo, M., Wree, A., Reissing, J., Demir, M., Vucur, M., Schierwagen, R., Stallmach, A., Kunstein, A., Bode, J., Trautwein, C., …, & Roderburg, C. (2024). Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS. Zeitschrift für Gastroenterologie, 62(09), e678. https://doi.org/10.1055/s-0044-1789816
Vancouver
Loosen S, Benz F, Mohr R, Reuken P, Wirtz T, Gu W, et al. Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS. Zeitschrift für Gastroenterologie. 2024;62(09):e678. doi:10.1055/s-0044-1789816
BibTeX
@article{Loosen2024,
author = {Loosen, S. and Benz, F. and Mohr, R. and Reuken, P. and Wirtz, T. and Gu, W. and Junker, L. and Jansen, C. and Meyer, C. and Praktiknjo, M. and Wree, A. and Reissing, J. and Demir, M. and Vucur, M. and Schierwagen, R. and Stallmach, A. and Kunstein, A. and Bode, J. and Trautwein, C. and Tacke, F. and Luedde, T. and Bruns, T. and Trebicka, J. and Roderburg, C.},
title = {Soluble urokinase plasminogen activator receptor (suPAR) levels predict survival in patients with portal hypertension undergoing TIPS},
journal = {Zeitschrift für Gastroenterologie},
year = {2024},
volume = {62},
number = {09},
pages = {e678},
doi = {10.1055/s-0044-1789816}
}
EUVIMED